Non-HDL cholesterol is the total amount of “bad” cholesterol in your blood. It’s calculated by a simple subtraction: take your total cholesterol number and subtract your HDL (the “good” cholesterol). What’s left is your non-HDL, and a healthy level for adults is less than 130 mg/dL.
This single number captures all the cholesterol types that can build up in your artery walls, which makes it a more complete snapshot of heart disease risk than the LDL number most people focus on.
What Non-HDL Actually Measures
A standard cholesterol test gives you several numbers: total cholesterol, HDL, LDL, and triglycerides. LDL gets the most attention because it’s the main driver of plaque buildup. But LDL isn’t the only cholesterol particle that damages your arteries. Your blood also carries other harmful types, including triglyceride-rich particles, their leftover remnants, and a particularly sticky particle called lipoprotein(a).
Non-HDL captures all of these in one measurement. Think of it this way: HDL is the only cholesterol type that actually helps protect your arteries by carrying cholesterol away. Everything else, to varying degrees, contributes to plaque. Non-HDL is simply “everything except the helpful kind.”
The formula is straightforward: total cholesterol minus HDL equals non-HDL. If your total cholesterol is 210 mg/dL and your HDL is 55 mg/dL, your non-HDL is 155 mg/dL. No extra blood draw or special test is needed. It’s already sitting in any standard lipid panel, even if your lab report doesn’t list it explicitly.
Why It May Matter More Than LDL
LDL cholesterol has been the standard target for decades, but it has a blind spot. About 22.7% of patients in one major clinical trial had a recurrent heart event within two years despite reaching low LDL levels and being on optimal medication. That residual risk points to something LDL alone doesn’t capture.
Multiple prevention trials, in both men and women and across different racial groups, have found that non-HDL is a better predictor of coronary artery disease risk than LDL. Among people already taking cholesterol-lowering medication, the association is even clearer: on-treatment non-HDL levels track more closely with future cardiovascular events than on-treatment LDL levels. A meta-analysis of over 130,000 statin-treated patients confirmed that while both LDL and non-HDL correlated with residual risk, non-HDL was more strongly linked to future events.
The reason comes down to particle count. Each cholesterol-carrying particle in the non-HDL family contains a protein called apolipoprotein B on its surface. Every one of these particles can penetrate your artery wall and trigger plaque formation, regardless of how much cholesterol it’s carrying. LDL is the most abundant of these particles, but it’s not the only one. Non-HDL captures the full set, giving a closer approximation of how many total harmful particles are circulating.
Healthy Ranges by Age and Risk
The National Institutes of Health defines these healthy non-HDL levels:
- Children and teens (19 and younger): less than 120 mg/dL
- Adult men (20 and older): less than 130 mg/dL
- Adult women (20 and older): less than 130 mg/dL
For people with diabetes, the American Diabetes Association sets the non-HDL target at less than 130 mg/dL, which corresponds to an LDL goal of less than 100 mg/dL. The non-HDL goal is typically set 30 mg/dL above whatever your LDL target is, since that 30 mg/dL gap accounts for the other atherogenic particles in your blood.
No Fasting Required
One practical advantage of non-HDL over LDL is that you don’t need to fast before the blood draw. LDL is usually calculated using a formula that depends on triglyceride levels, and triglycerides spike after eating. That makes the LDL calculation less reliable in a non-fasting sample.
Non-HDL sidesteps this problem. Research on both statin-treated and untreated patients found that non-HDL levels were essentially the same whether people had fasted or not. In the statin-treated group, fasting and non-fasting values showed 0% difference. In untreated patients, the difference was only 1.5%. That’s clinically negligible, which means your non-HDL result is trustworthy even if you ate breakfast before your blood test.
Lowering Non-HDL With Lifestyle Changes
Diet and exercise both help, but combining them produces the most reliable results. A meta-analysis of randomized controlled trials found that diet changes alone (reducing saturated fat, cutting calories) lowered non-HDL by about 8.5 mg/dL on average, a 5.6% reduction. Exercise alone didn’t produce a meaningful change. But when diet and exercise were combined, non-HDL dropped by an average of 11.1 mg/dL, a 6.5% reduction, and this was the only group where the result was statistically significant.
These interventions lasted at least four weeks and included standard heart-healthy dietary patterns: lower saturated fat intake, calorie control, and increased fiber. The takeaway is that dietary changes do the heavy lifting, while adding regular aerobic exercise amplifies the effect.
What Medication Can Do
When lifestyle changes aren’t enough, statins are the primary tool for bringing non-HDL down. The UK’s National Institute for Health and Care Excellence sets a target of reducing non-HDL by more than 40% from baseline when high-intensity statins are prescribed. In clinical trials, the most effective options at high intensity lowered non-HDL by roughly 85 to 90 mg/dL compared to placebo.
The goal of treatment isn’t just to lower the number for its own sake. Because non-HDL reflects the total burden of artery-damaging particles, reducing it means fewer particles available to penetrate your artery walls and fewer opportunities for plaque to grow. For people already on a statin, tracking non-HDL gives a more accurate picture of whether the medication is adequately controlling their risk than tracking LDL alone.
How Non-HDL Fits With Other Tests
Non-HDL is part of a broader shift in how heart disease risk is assessed. The most precise marker available is a direct measurement of apolipoprotein B, the protein on every harmful cholesterol particle. When researchers compare situations where LDL, non-HDL, and apolipoprotein B levels tell different stories (say, normal LDL but high apolipoprotein B), cardiovascular risk consistently follows apolipoprotein B and non-HDL rather than LDL.
Not every lab automatically reports apolipoprotein B, and it requires a separate test. Non-HDL, by contrast, costs nothing extra and is available from any routine lipid panel. That combination of accuracy and accessibility is why many guidelines now recommend paying attention to non-HDL alongside, or even instead of, LDL as the primary cholesterol target. If your lab report doesn’t list it, you can calculate it yourself in seconds from the numbers already there.